Chi, Yongsheng 遲永勝

Censure of Fusen Pharma (1652) and 5 directors
SEHK, 4-Jan-2023
The firm was listed in mid-2018 after raising HK$397m. It spent most of 2019 siphoning off RMB258m in unapproved "advances" to a company half-owned by Cao Changcheng, the founder, Chairman and controlling shareholder of Fusen Pharma. The funds were (apparently) repaid by Christmas Day that year.

Sign up for our free newsletter

Recommend Webb-site to a friend

Copyright & disclaimer, Privacy policy

Back to top